Latest Breaking News On - நேரடி சோடியம் அகற்றுதல் - Page 1 : comparemela.com
Investegate |Sequana Medical NV Announcements | Sequana Medical NV: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Sequana Medical NV: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sequana Medical NV: Sequana Medical s results from RED DESERT alfapump DSR study presented as one of the Highlights at Heart Failure 2021 Online Congress
the Company or Sequana Medical
), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of
alfapump DSR (Direct Sodium Removal) which were presented at the Heart Failure 2021 Online Congress as part of the Late Breaking Science Results were also selected for the congress Highlights session, held virtually on 1 July 2021.
Dr
,
, at the Heart Failure 2021
Online
a
improvement in diuretic response.
Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
ii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures.
Sequana Medical NV: Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study (POSEIDON)
i
All patients experienced
Safety
Primary endpoint read-out
Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
vimarsana © 2020. All Rights Reserved.